Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea's Economy Minister Pledges Support for Local Biosimilar Companies

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Emphasizing the importance of biosimilars for the country's economic growth potential in coming years, Knowledge Economy Minister Choi Kyung-Hwan - one of South Korea's top economic leaders - assured industry that the ministry will help local pharmaceutical outfits lay a solid foundation for the burgeoning biosimilar sector

You may also be interested in...



New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies

SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices

New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies

SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices

Korean Government Announces Joint Fund To Beef Up Local Pharma Industry

SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC070697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel